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A B S T R A C T
We have previously reported presence of the glucocorticoid (GC) receptor (GR) alpha on blood platelets,
and its ability to modulate platelet aggregation when activated by the synthetic GC prednisolone (Pred).
In the present study we investigated the effects of Pred on broader aspects of platelet functions to unveil
novel non-genomic actions on this cell type. Using whole blood assay we demonstrated that Pred was the
only GC able to inhibit platelet aggregation and platelet–monocyte interactions. This latter effect was
due to regulation of platelets, not monocytes. We next examined the effects of Pred on physiological
actions of platelets, observing inhibition of platelet adhesion and spreading on collagen under static
conditions. Moreover Pred inhibited thrombus formation under ﬂow, suggesting potential important
effects in haemostasis and thrombosis. Pred was unable to regulate platelet reactivity under conditions
where the effects of platelet-derived ADP and TxA2 were blocked, suggesting that the GC targeted the
activation-dependent component of the adhesion and aggregation response. The effects of Pred were not
mediated through cyclic nucleotide signaling, but rather seemed to evolve around selective regulation of
P2Y12 ADP receptor signaling, intimating a novel mode of action. This study details the actions of Pred on
platelets unveiling novel properties which could be relevant for this GC in controlling unwanted vascular
and thrombotic diseases.
 2012 Elsevier Inc. 
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In virtually all cell types, glucocorticoids (GC), lipophilic
compounds with rapid diffusion through the plasma membranes,
bind to cytosolic glucocorticoid receptors (GR) to form a receptor
complex which acts as a transcription factor affording remarkable
modulation of gene expression [1,2]. The GC/GR complex can exist
either as a monomer or a dimer; while the monomer will remain in
the cytosol, affecting signaling cascades and gene promoter
activity indirectly, the dimer translocates into the nucleus, binds
to the GC response elements present in promoter regions of target
genes, hence modulating gene expression directly. Alongside these
classical GR responses, which are in line with those of other sex
hormone receptors, more rapid effects have been recently reported
for GC, classiﬁed as ‘‘non-genomic’’, since they do not involved
genetic modiﬁcation [3]. The detailed mechanisms of GR activation
by GCs to elicit ‘‘non-genomic’’ effects are still unclear, though
some hypothesis have been put forward [4]: GC can affect cell* Corresponding author. Tel.: +44 01482 461905.
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Open access under CC BY license.responsiveness by accumulating into plasma membranes changing
cell physic-chemical properties [5]. Furthermore, selective mem-
brane effects can be elicited in view of the existence of membrane
receptor sites on monocytes [6]. However, GC binding to classical
GR can also initiate rapid non-genomic responses, including
modulation of T cell receptor-mediated phospho-signalosome
[7,8] and annexin A1 phosphorylation and secretion in neutrophils
[9].
Our previous work has revealed the unexpected ﬁnding that GR
activation can modulate platelet function [10]. These cells play a
key role in haemostasis and thrombosis and, being anucleate cells,
they represent the ideal model to study the non-genomic effects of
GC. Indeed, we reported that prednisolone (Pred), but not
dexamethasone (Dex), inhibits platelet aggregation in vitro [11].
Since most laboratories use Dex as a reference GC for in vitro
studies, this differential efﬁcacy would provide an explanation
why the effects of GC on human platelets have been neglected for
so long. Of relevance, the inhibitory effect of Pred was reversed by
pre-incubation with the GR antagonist mifepristone, suggesting
the functional importance of the classical GR/GC complex also in
the inhibition of platelet aggregation in platelet-rich plasma [11].
Blood platelets play an established role in the thrombotic
complications arising from atheroma-induced vascular rupture,
and they can also contribute to the inﬂammatory responses
leading to endothelial dysfunction [12]. Thus the potential
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provides an interesting addition to their clinical usage. In the
present study we set out to characterize the effects of Pred in
human platelet functions, spanning from monitoring aggregation,
using a whole blood protocol, to establishing the effect of this GC
on other responses of activated platelets, including formation of
platelet/monocyte aggregates and platelet adhesion under arterial
ﬂow. Our data demonstrate that in whole blood Pred, but not other
GCs, modulate platelet-platelet interactions, platelet–monocyte
interaction and thrombosis under conditions of ﬂow in a GR-
dependent manner. Collectively, these results shed novel light on
the biology of Pred in relation to the human platelet and, in view of
its widespread application for the management of several clinical
conditions, may have bearing to human pathology.
2. Materials and methods
Unless otherwise speciﬁed, all chemicals were from Sigma–
Aldrich (Poole, UK).
2.1. Blood collection and platelet isolation
Human blood was collected from healthy volunteers, who had
abstained from non-steroidal anti-inﬂammatory drugs medica-
tions at least for the preceding 7 days, using venepuncture into
hirudin (1:9, Instrumentation laboratory, Warrington, UK). All
experiments were approved by the East London Research Ethics
Committee (no. 05/Q0603/34).
For preparation of washed platelets, blood was taken into acid
citrate dextrose (ACD: 29.9 mM sodium citrate, 113.8 mM glucose,
72.6 mM sodium chloride and 2.9 mM citric acid, pH 6.4) as
anticoagulant. Platelet-rich plasma (PRP) was obtained by centrifu-
gation of whole blood at 200 g at 20 8C for 20 min. PRP was treated
with citric acid (0.3 mM) and centrifuged at 1900 rpm for 12 min.
The platelet pellet was then suspended in wash buffer (36 mM citric
acid, 10 mM EDTA, 5 mM glucose, 5 mM KCl, 9 mM NaCl) and spun
once more. Platelets were ﬁnally re-suspended at a concentration of
5  107 or 2.5  108 platelets/ml in modiﬁed Tyrodes buffer
(150 mM NaCl, 5 mM HEPES, 0.55 mM NaH2PO4, 7 mM NaHCO3,
2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM glucose) unless otherwise
stated.
2.2. Platelet aggregation
Whole blood impedance aggregometry was applied using a
MultiplateTM analyzer (Instrumentation Laboratory, Munich,
Germany). Thirty minutes after venepuncture, 300 ml of hirudinated
blood was diluted 1:1 with saline (0.9% w/v, Sigma–Aldrich) into a
test cell at 37 8C and stirred for 3 min in presence of one or
combination of GCs; prednisolone (Pred), dexamethasone (Dex),
nitro-dexamethasone (Nitro-Dex), ﬂudrocortisone (Fludro), triam-
cinolone (Triam) before the addition of either collagen (3.2 mg/ml;
Instrumentation Laboratory), arachidonic acid (AA, tested at 0.5 and
0.25 mM; Instrumentation Laboratory) or adenosine-diphosphate
(ADP, tested at 3.2 and 6.5 mM; Instrumentation Laboratory). The
electrical resistance between two pairs of silver coated wires was
measured and plotted over a 6-min period. The MultiplateTM
analyzer calculated the average area under the curve (AUC) for the
two readings. Each test was conducted in duplicate for each donor
sample.
Alternatively, washed platelets (250 ml; 2.5  108 platelets/ml)
were incubated for 5 min at 37 8C in a multichannel Chronolog
Aggregometer (Pennsylvania, USA) prior to stimulation to allow for
temperature equilibration. The platelet suspension was then
stimulated with ADP (5 mM) under stirring conditions
(1000 rpm) and platelet aggregation was recorded for 4 min.The platelet aggregometer was recalibrated for every individual
platelet sample used. The following incubation times were used for
inhibitors added prior to stimulation of platelets; A3P5P (300 mM
for 1 min), MRS2395 (10 mM for 1 min) and Pred (1 or 10 mM for
5 min) prior to the addition of ADP (10 mM).
2.3. Platelet–monocyte aggregation assay
The formation of platelet–leukocyte aggregates in the whole
blood was analyzed by pre-incubating 100 ml of blood with
antibodies (diluted 1:50) against human CD42b (FITC-conjugated;
clone HIP1; eBioscience, Hatﬁeld, UK) and CD14 (PE-conjugated;
clone 61D3, eBioscience, Hatﬁeld, UK) and either Pred or vehicle for
3 min at 25 8C. Platelets were stimulated by adding ADP (1–3 mM)
and incubated for a further 20 min at 25 8C. Samples were ﬁxed and
red blood cells (RBC) lysed using BD FACSTM lysing solution (BD
Bioscience; 1:10 ﬁnal dilution) and kept at 4 8C up to analysis.
In some cases, Pred was added to either the platelet or the
leukocyte preparation separately. To this end, after removing PRP,
the remaining of the blood was resuspended in RPMI 1640
(BioWhittaker, Wokingham, UK) (ratio 1:1) and mononuclear cells
separated through a double density gradient as previously described
[17]. Both PRP and mononuclear cells pretreated with either Pred
(5 nM–5 mM) or vehicle for 5 min at 25 8C. Following a washing step,
platelets and mononuclear cells were re-suspended in Hepes buffer
(NaCl 150 mM, KCl 5 mM, MgSO4 1 mM, HEPES 10 mM) and added
to tubes in equal volume. After addition of FITC-conjugated anti-
human CD42b and PE-conjugated anti-human CD14, samples were
stimulated with ADP (1–3 mM) and incubated for 20 min at 25 8C
then ﬁxed using paraformaldyde (4%, Sigma–Aldrich, Poole, UK) and
stored at 4 8C prior analysis. Flow cytometry was performed on a
FacsCalibur analyzer (Becton Dickinson, Oxford, UK). Platelets and
monocytes were discriminated by forward and side light scatter,
identiﬁed by their positive staining for FITC-CD42b or PE-CD14,
respectively. Events double positive for FITC and PE identiﬁed
platelet–monocyte aggregates and were recorded as a percentage of
a total of 10,000 gated monocytes.
2.4. Fluorescence microscopy
Platelets (5  107/ml) the presence and absence of the
appropriate inhibitors were adhered to collagen (10 mg/ml)-
coated coverslips for 30 min at 37 8C. After incubation, coverslips
were washed with PBS to remove non-adherent platelets. For
experiments with Pred, the GC was added to platelets 5 min before
addition to slides. The following incubation times were used for
inhibitors added prior to adhesion of platelets: apyrase (2 U/ml for
1 min), indomethacin (10 mM for 5 min), ODQ (20 mM for 15 min)
or myrPKI (500 nM for 15 min). Adherent platelets were ﬁxed with
3.5% paraformaldehyde and permeablized with 0.2% Triton-X-100
in PBS. Platelets were stained for F-actin using TRITC-conjugated
phalloidin and visualized using ﬂuorescent microscopy (IX71,
Olympus, Kyoto, Japan). For each experiment, the numbers of
platelets from eight random ﬁelds of view were added, and the
results were calculated as mean number of adherent platelet per
0.01 mm2. The average surface area of the individual adherent
platelets was calculated using Cell P software (Olympus).
2.5. Analysis of protein phosphorylation in platelets
Washed platelets (2  108 platelets/ml) were pre-treated with
either ODQ (20 mM) or myrPKI (500 nM) for 10 min and then
incubated with either the nitric oxide donor, S-nitrosoglutathione
(GSNO; 10 mM) or prostaglandin E1 (1 mM) for 2 min. Platelets
were lysed by the addition of Laemmli sample buffer (1). Proteins
were separated by sodium dodecylsulfate polyacryl-amide gel
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immunoblotted as previously described [13]. Membranes were
with either anti-VASP-phospho239 or anti-VASP-phospho157 anti-
bodies (1:1000).
2.6. Platelet aggregation under ﬂow
Platelets (2  108 platelets/ml) were incubated with dihexlox-
acarbocyanine (DIOC6; 1 mM) at 37 8C for 10 min and then
incubated at 37 8C for 2 min with Pred (10 mM), before being
reconstituted with autologous washed RBC. Flow studies were
performed using glass capillary tubes (Camlab; Cambridge, UK),
coated with immobilized collagen (100 mg/ml; Nycomed, Zurich,
Switzerland) for 12 h, blocked with BSA/PBS (5 mg/ml) for 1 h and
washed under ﬂow conditions with PBS for 4 min. Platelets were
perfused through collagen-coated capillary tubes at 1000/s1 for
4 min, followed by washing (4 min) at the same shear rate.
Adherent platelets/thrombus formation was visualized using
ﬂuorescence microscopy (IX71, Olympus). Data were calculated
from the percentage of the area covered by adhering platelets in a
deﬁned area (surface coverage), since this methodology cannot
fully discriminate between individual platelets and platelet
aggregates [14]. For each experiment 10 random ﬁelds of view
used to calculate surface coverage (%) using ImageJ software (NIH).
2.7. Statistics
Experiments were conducted in duplicate or triplicate and
repeated at least 3 times. Data are reported as mean  SEM.
Statistical differences were analyzed by ANOVA followed by
Dunnett’s test or by Student’s t test, as appropriate. A P value less
than 0.05 was taken as signiﬁcant.
3. Results
3.1. Prednisolone inhibits platelet function in whole blood
Incubation of whole blood with Pred (5 nM–10 mM) led to a
concentration-dependent inhibition of ADP-induced platelet aggre-
gation (Fig. 1A and B). Modest inhibitory effects were observed with
concentrations as low as 5 nM, with optimal inhibition of
aggregation observed at 500 nM, when aggregation was reduced
by 22  4% (n = 5). Increasing the concentration to supra-physiological
levels such as 10 mM failed to augment the extent of inhibition afforded
by Pred. In the same settings, aspirin (20 mg/ml) produced 70%
inhibition of ADP platelet aggregation (not shown). In any case, the
inhibitory effects of Pred were rapid, being established within 3 min of
incubation and remained consistent for up to 60 min (longest time
tested) post-steroid application (Fig. 1C). There were no signs of
tachyﬁlaxis, so the double addition of Pred at both 3 and 60 min prior to
ADP addition, did not lead to a reduced extent of inhibition (Fig. 1C). In
the whole blood assay, Pred (tested at 10 mM) failed to signiﬁcantly
attenuate platelet aggregation elicited by arachidonate or collagen
(Table 1).
Next we aimed to determine whether these inhibitory
properties of Pred were shared by other GCs and therefore
compared its anti-platelet actions with those of Dex, Nitro-Dex,
ﬂudrocortisone, triamcinolone and a combination of the latter two.
Consistent with previous experiments Pred inhibited aggregation
in whole blood (19  3%; P < 0.05). Nitro-Dex also caused a
signiﬁcant inhibition of aggregation (29  7%; P < 0.05), although
this is likely to be related to the NO-donor properties since the parent
compound Dex alone had no effect. Fludrocortisone and triamcino-
lone were also ineffective platelet regulators (Fig. 1D). Similar results
were obtained when the same GCs were tested in PRP, conﬁrming the
unique key property of Pred (Fig. 1E).3.2. Pred modulates platelet–monocyte interactions in whole blood
To determine the breath of Pred effects on platelet functions,
beyond aggregation [11], a ﬂow cytometry protocol was applied to
examine platelet–monocyte aggregate formation. Addition of ADP
(1 and 3 mM) to whole blood produced a clear increase in platelet–
monocyte interactions (Fig. 2A), with 28  5 and 45  4% aggregate
formation, respectively (compared to background). Pre-incubation of
whole blood with Pred (from 5 nM to 5 mM; 3 min) prior to ADP led to
a concentration-dependent inhibition of platelet/monocyte aggre-
gates. For instance, at 5 nM Pred caused 20  4% inhibition of ADP
(used at 1 mM) induced aggregates formation, while maximal effects
(32  2%; P < 0.05) were observed with the 500 nM concentration.
This GC retained its inhibitory effect also when a higher concentration
of ADP (3 mM) was used, though the highest concentration tested of
5 mM was required to attain signiﬁcant inhibition (Fig. 2B).
To clarify if one of the two cell types selected was a preferable
target for the GC, we treated PRP and monocytes separately with
Pred (500 nM), before reconstituting the co-culture system and
stimulating with ADP (1 mM). When both cell types were treated
with Pred, we observed a 30  6% inhibition of aggregate formation
(P < 0.05) (Fig. 2C). When platelets alone were exposed to the GC, its
ability to inhibit platelet–monocyte aggregates was still apparent
albeit slightly reduced (12  4% reduction). However, if the mono-
cytes were selectively treated with Pred, no inhibition of cell
aggregates could be observed (Fig. 3C). Taken together with the
platelet-to-platelet aggregation data, these results identify platelets
as a primary cellular target for Pred, and they also underline that the
properties of this GC are maintained even in the presence of other
cells, increasing its physiological and pharmacological relevance.
3.3. Prednisolone inhibits platelet adhesion and spreading on
immobilized collagen
Having established that Pred inhibits platelet aggregation, a
response that relies on integrin-mediated platelet-platelet inter-
action [15], we next explored whether the GC could also affect
platelet-extracellular matrix interactions by examining platelet
adhesion to collagen. Using ﬂuorescence microscopy, we observed
that incubation of washed platelets with collagen-coated cover-
slips led to a marked degree of cell adhesion (43.2  4.7 platelets/
0.01 mm2). When platelets were pre-incubated with Pred a concen-
tration dependent inhibition of adhesion was observed. Threshold
effects were observed with 1 mM Pred, with a number of adherent
platelet reduced to 21.8  4 platelets/0.01 mm2, while maximal
effects occurred at 10 mM Pred, when adherent platelets fell to
6.8  2.9 (hence > 80% reduction; P < 0.01) (Fig. 3B). In addition to
reducing the number of adherent platelets, Pred also inhibited the
ability of platelets to spread on collagen (measured as surface area).
At 10 mM Pred, platelet spreading was reduced from 29.5  1 in the
absence of Pred to 2.3  1 mm2 (P < 0.05) in the presence of values
Pred. The inhibitory effects of Pred (10 mM) on platelet adhesion to
collagen were reversed by the GR antagonist, RU486 (10 mM; Fig. 3C).
Similarly, where Pred (10 mM) reduced platelet spreading from
29.5  1 to 2.3  1 mm2, the mean surface area remained at
24.1  1.8 mm2 in the presence of RU486. Similar data were obtained
using ﬁbrinogen as the adhesive surface (Supplementary Fig. 1). Of
interest, we tested Dex (10 mM) in this assay and it resulted inactive
(data not shown), in line with the results obtained with the
experiments of whole blood aggregation.
3.4. Pred inhibits platelet adhesion by targeting secondary mediator
induced platelet activation
Having established the ability of Pred to regulate a number of
platelet functions, we began to examine the potential mechanisms.
Fig. 1. Prednisolone inhibits ADP-induced platelet aggregation in whole blood. (A) Representative platelet aggregation curves as determined with the whole blood
aggregometer, allowing quantiﬁcation of the area under the curve (AUC). Curves are from ADP (3.25 mM) with or without Pred (10 mM), showing duplicate readings. (B)
Concentration–response curve for Pred against ADP (3.25 mM) as stimulus; n = 5, *P < 0.05 compared with untreated samples. (C) Lack of tachyﬁlaxis to Pred effect. The GC
was incubated with the blood for 3 min, 60 min or 3 + 60 min (added twice) prior to ADP-induced aggregation. Data, mean  SEM of 3 experiments, are reported as % of
inhibition as compared to appropriate control samples, were vehicle was added; *P < 0.05 compared to control. (D) The reported GC were tested in the whole blood assay, using a
3 min pre-incubation period and ADP (3.25 mM) as stimulus. Prednisolone (Pred, 10 mM), dexamethasone (Dex, 10 mM), Nitro-dexamethasone (Nitro-Dex, 10 mM), triamcinolone
(Triam, 10 mM), ﬂudrocortisol (Fludro, 10 mM) and a combination of Fludro and Triam (5 mM each); data are mean  SEM of 5 distinct experiments; *P < 0.05 compared to vehicle.
(E) As in (D) except experiments were conducted with platelet rich plasma (PRP). Data are mean  SEM of 4 distinct experiments; *P < 0.05 compared to vehicle.
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activation-dependent cognate response, driven through platelet
derived ADP and TxA2 [13]. Hence, we investigated the role of these
soluble agonists in the effects of Pred. The joint presence of apyrase
(1 U/ml) and indomethacin (10 mM), reduced platelet adhesion byTable 1
Stimulus-dependency for Pred inhibition of platelet aggregation in whole blood.
Agonist ADP (mM) 
6.50 3.22 1.5
Inhibition (%) 22.7  5.6* 19.2  4.0* 2.0
Platelets were incubated with 5 mM prednisolone for 3 min prior to stimuli addition (co
Values (mean  SEM) report the percentage of inhibition as calculated for each stimulus/c
* P < 0.05 as calculated on the original values.36  4 platelets/0.01 to 12.3  7.2 mm2 (60% inhibition; P < 0.05),
conﬁrming that maximal adhesion requires substantial platelet
activation driven by platelet-derived metabolites (Fig. 4B). Pred
(10 mM) reduced the number of adhered platelets to 9.0  3.0
platelets per 0.01 mm2 (Fig. 4). When apyrase/indomethacin-treatedArachidonic acid (mM) Collagen
6 250 500
  1.0 4.0  1.0 2.0  1.0 9.5  2.0
llagen was used at 3.2 mg/ml) and aggregation monitored as described in Section 2.
oncentration out of 5 distinct experiments.
Fig. 2. Prednisolone preferentially targets the platelet to inhibit platelet/monocyte aggregate formation. Formation of platelet/monocyte aggregates was investigated using
ﬂow cytometry. (A) Top let panel: scatter plot indicating the monocyte population (gate). Top right panel, plot for CD42b and CD14 in unstimulated identiﬁes the quadrant for
double positive events. Bottom right, blot after ADP (3.25 mM) addition. Bottom left, Pred (5 mM) was incubated for 5 min with the blood prior to ADP addition: note the lower
extent of double positive events. (B) Concentration response for Pred inhibition of aggregates formation upon stimulation with 1.56 (closed squares) or 3.25 (closed triangles)
mM ADP. Data are mean  SEM of 5 experiments performed in triplicate; *P < 0.05 compared to vehicle. (C) Identiﬁcation of the platelet as the main target for Pred. Monocytes and
platelets were exposed, contemporarily or separately, to 500 nM Pred for 3 min prior to reconstitution and stimulation with 1.56 mM ADP. Data are mean  SEM of 5 experiments
performed in triplicate; *P < 0.05 compared to vehicle.
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to collagen, which was not signiﬁcantly different to that attained by
the combination apyrase/indomethacin alone. Thus, collagen-in-
duced adhesion and spreading in the presence of apyrase/indometh-
acin is unaffected by Pred, indicating that the inhibitory actions of the
GC are targeting the secondary mediator-induced activation-depen-
dent component of the platelet adhesion process.
To further understand how Pred was regulating the actions of
secondary mediators, we examined whether individual ADP
receptors were being targeted. In order to simplify the experimen-
tal approach, we examined aggregation of washed platelets
stimulated with ADP (5 mM) in the presence of MRS2395
(10 mM) and A3P5P (300 mM) to inhibit the potential effects of
ADP signaling through P2Y1 and P2Y12 receptors respectively.Under these conditions Pred reduced aggregation from 68  4 to
43  7 (P < 0.05), while A3P5P and MRS2395 reduced aggregation to
46  8 and 36  7% respectively (P < 0.05). Interestingly when
platelets were treated with prednisolone in combination with
A3P5P, aggregation was reduced to 36  5%, which was no different
to when the inhibitors were used independently. In contrast, a
combination of prednisolone with MRS2395 reduced aggregation to
22  3% (P < 0.05 when compared to either inhibitor used alone)
(Fig. 4C). These data suggest that prednisolone may have the capacity
to target P2Y12/Gi signaling.
Previously, we and others have shown that cAMP and cGMP
signaling pathways reduce the release and activity of platelet
ADP and TxA2 under both stirred and static conditions [16]. To
explore this as a potential route of action for Pred, platelets were
Fig. 3. Prednisolone potently inhibits platelet adhesion and spreading on collagen. Glass slides were coated overnight at 4 8C with collagen (100 mg/ml), or heat-denatured
humans serum. Uncoated surfaces were blocked by overlay with heat inactivated human serum albumin (HSA, 5%) for 30 min at 20 8C. Washed platelets (5  107 platelets/
ml) were pre-incubated with Pred (5 min) (0.1, 1 and 10 mM) in the presence and absence of RU486 and adhered for 30 min, stained with TRITC-phalloidin and viewed using
the 60 magniﬁcation. (A) Representative images. Bar, 20 mm. (B) Platelets from 8 random visual ﬁelds with a total area of 0.1 mm2were counted and expressed as number of
adherent platelets/0.1 mm2. (C) These images were used to determine platelet surface area, presented the mean surface area (mm2)  SEM. All data shown are mean  SEM,
n = 5 with separate blood donors. *P < 0.05 compared to collagen alone.
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(20 mM) or the protein kinase A inhibitor myristolated PKI
(500 nM). Under these conditions, Pred continued to inhibition
platelet adhesion to collagen (Fig. 5A and B). These inhibitors
blocked both nitric oxide and prostaglandin E1 induced
phosphorylation of VASP on serine239 and 157, markers of
protein kinase G and A respectively, conﬁrming their activity
under the conditions we employed (Fig. 5C). Supplementary Fig.
2 indicates that it is unlikely Pred could affect cAMP levels.3.5. Platelet aggregation under conditions of ﬂow
Finally, we examined the ability of Pred to regulate thrombus
formation in response to collagen under shear conditions using an
in vitro ﬂow based assay. Under shear (1000 s1), immobilized
collagen (100 mg/ml) supported adhesion of numerous small
thrombi that covered 14.7  1.8% of the collagen-coated surface
(Fig. 6). Pretreatment of platelets with Pred (10 mM) reduced surface
coverage of collagen-coated microslides to 6.7  1.1% (P < 0.01).
Fig. 4. Prednisolone effect on platelet adhesion under conditions that abrogate ADP and TxA2 activity. Glass slides were coated overnight at 4 8C with collagen (100 mg/ml), or
heat-denatured humans serum. Uncoated surfaces were blocked by overlay with heat inactivated human serum albumin (HSA, 5%) for 30 min at 20 8C. Washed platelets
(5  107 platelets/ml) were pre-incubated with Pred (5 min; 10 mM) in the presence and absence of apyrase (Ap; 2 U/ml) and indomethacin (Indo; 10 mM), and then adhered
for 30 min, stained with TRITC-phalloidin and viewed using the 60 magniﬁcation. (A) Representative images. Bar, 20 mm. (B) Platelets from 8 random visual ﬁelds with a
total area of 0.1 mm2 were counted and expressed as number of adherent platelets/0.1 mm2. All data shown are mean  SEM, n = 4 with separate blood donors. *P < 0.05
compared to collagen alone. (C) Washed platelets (2.5  108 platelets/ml) pre-incubated with Pred (1 mM) and then stimulated with ADP (5 mM) alone or in the presence of A3P5P
(300 mM) or MRS2395 (MRS; 10 mM), and the aggregation response was monitored for 4 min under constant stirring. All data shown are mean  SEM, n = 4 with separate blood
donors. *P < 0.05 compared to ADP in the presence individual inhibitors, §P < 0.05 compared aggregation with either Pred or MRS2395 alone.
E. Liverani et al. / Biochemical Pharmacology 83 (2012) 1364–137313704. Discussion
There is mounting evidence that GC can also exert biological
effects through non-genomic modalities. Recently we demonstrat-
ed that the synthetic GC Pred modulated platelet aggregation,
through a mechanisms that involved engagement of the classical
GR [11]. Since both platelets and GCs play important roles in the
inﬂammation response, their interactions may have an important
impact on a number disease states. The aim of the present studywas to extend our initial observations to whole blood, a more
physiologically relevant environment, and determine if this GC
affected broad aspects of platelet function. We report that Pred, but
not other GC, is active in the whole blood milieu and modulates
both platelet-platelet and platelet–monocyte interactions. Fur-
thermore, new data demonstrate that Pred reduces platelet
adhesion and spreading, potentially through targeting the activa-
tion-dependent component of platelet adhesion to collagen.
Importantly the downstream consequence of these actions, was
Fig. 5. Role of Pred on the cGMP-signaling pathway. Glass slides were coated
overnight at 4 8C with collagen (100 mg/ml), or heat-denatured humans serum.
Uncoated surfaces were blocked by overlay with heat inactivated human serum
albumin (HSA, 5%) for 30 min at 20 8C. Washed platelets (5  107 platelets/ml) were
pre-incubated with Pred (5 min; 10 mM) in the presence and absence of either ODQ
(20 mM) or myrPKI (500 nM), and then adhered for 30 min, stained with TRITC-
phalloidin and viewed using the 60 magniﬁcation. Platelets from 8 random visual
ﬁelds with a total area of 0.1 mm2 were counted and expressed as number of
adherent platelets/0.1 mm2 (A) and platelet surface area (mm2) (B), all data shown
are mean  SEM, n = 4 with separate blood donors. *P < 0.05 compared to collagen
alone. (C) Washed platelets were pre-treated with either ODQ (20 mM) or myrPKI
(500 nM) for 10 min and then incubated with either the nitric oxide donor, S-
nitrosoglutathione (GSNO; 10 mM) or prostaglandin E1 (1 mM) for 2 min. Platelets
were lysed and immunoblotted with either anti-VASP-phospho239 or anti-VASP-
phospho157 antibodies.
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conditions of ﬂow.
Our ﬁrst critical observation was that Pred regulated platelet
activity in whole blood, suggesting that the agent could be active
against platelets in the circulation, a ﬁnding with obvious clinical
bearing. Using the whole blood protocol, Pred induced a signiﬁcant
inhibition of ADP-induced aggregation, but was ineffective when
collagen and AA were used to stimulate aggregation. These data are
in part consistent with observations conducted with PRP and the
aggregation assay; in the whole blood protocol Pred afforded only a
modest effect on collagen-induced aggregation, while it affected
collagen-induced responses in PRP [11]. We explain this apparent
discrepancy because collagen can also stimulate neutrophils in the
whole blood protocol [17], an effect that could mask inhibition of
platelet aggregation. In fact, lower concentrations of collagen and
AA may have inhibited aggregation to a signiﬁcant extend,
however the concentrations selected were the ones providing
more reliable and consistent results in whole blood settings. Our
new analyses showed that Pred inhibition of aggregation was
maintained over time, since results obtained after 3 min werecomparable to what observed following 1 h pre-incubation.
Interestingly, Pred was unique in this ability [18], since the other
GC tested failed to have any effect. We examined a number of
different synthetic steroids, selected because of their differing
afﬁnities for GR [19]. Pred and ﬂudrocortisone have shown an
higher afﬁnity for GR, but can also bind the mineralocorticoid
receptor (MR) [20,21], Dex binds strictly bind GR [20], while
triamcinolone [22] appears to be similar to Dex but with low
afﬁnity for the MR. In any event, Pred remained the only GC able to
engage platelet GR to elicit non-genomic inhibitory responses. The
NO-donating GC [23], Nitro-Dex, did inhibit aggregation, but this
effect is clearly due to the NO moiety, which releases NO in
biological ﬂuids, and not to the GC moiety since Dex alone was
ineffective. GR is a peculiar receptor, since it acts as a complex of
which the ligand is fully part of [3,24]; we postulate that the side
groups attached to the GC core structure of Pred are able to activate
platelet GR in a speciﬁc and selective manner, though the
structural motifs and reasons behind this would be the scope
for future studies. Similar stringent structural motif can be
postulated for Pred interaction (and activation thereof) with MR,
since ﬂudrocortisone was inactive in these settings. Altogether,
this remains an intriguing set of data that might require thorough
molecular pharmacology investigations to be clariﬁed.
An increase of heterotypic leukocyte-platelet aggregates has
been reported cardiovascular disease [25,26], which may contrib-
ute to their inﬂammatory component(s). Furthermore, reduction of
the formation of these heterocellular aggregates is attained by
widely used anti-platelet therapies such those presugrel or
clopidogrel [27]. We found that, consistent with clinically used
anti-platelet agents, Pred was a highly effective inhibitor of ADP-
induced platelet/monocyte aggregate in whole blood. In addition,
we could unveil a preferential effect on platelet, and not monocyte,
reactivity as demonstrated by the re-constitution experiments. We
conclude that platelet GR may be endowed with ‘higher
modulatory’ function in the control of aggregate formation, a
feature that is currently being extended to inﬂammatory
pathologies too [26].
At sites of vascular injury platelet accumulation begins with an
interaction between the extracellular matrix collagen and the
platelet receptor glycoprotein VI [28]. This leads to activation of
integrin a2b1 which then allow stable adhesion and facilitate
spreading [29], a pre-requisite to thrombus formation [30]. Pred
was extremely effective in inhibiting this fundamental platelet
response, as measured by the extent of adhesion and spreading of
platelets on collagen. A proportion of the adhesion response to
collagen was resistant to Pred since complete inhibition was never
attained regardless of the concentration applied. The effects of Pred
on adhesion and spreading were lost under conditions where the
effects of secondary signaling by ADP and TxA2 were abrogated.
These data suggest strongly that Pred targets secondary signaling
required for maximal platelet adhesion (hence the lack of complete
inhibition) and is consistent with our observation that Pred
preferentially targets ADP-induced aggregation and limit TxA2
synthesis [11].
The argument is further strengthen by aggregation data using
combinations of Pred with known ADP receptor antagonists
MRS2395 and A3P5P. In the presence of the P2Y12 inhibitor A3P5P,
the ability of Pred to inhibit platelet was lost, while with
combination of MRS2395, a P2Y1 antagonist, we observed an
additive effect of Pred, strongly suggesting that this GC regulates
AD-induced platelet activation through modulation of the P2Y12/Gi
signaling pathway. We also found that in whole blood, Pred did not
inhibit aggregation induced by either AA or collagen, which is in
contrast to the data obtained using PRP. It is possible that the
effects of Pred could be masked here due to the high concentrations
of agonist required in whole blood assays, negating the reliance on
Fig. 6. Prednisolone inhibits thrombus formation on collagen in vitro. Washed platelets were stained with DiOC6 (1 mM), incubated with Pred (10 mM) or vehicle for 2 min and
reconstituted blood was ﬂowed over immobilized collagen (100 mg/ml) for 4 min at a indicated shear rate of 1000/s1. Platelet deposition viewed by ﬂuorescence microscopy
[21]. Images from 8 random ﬁelds of view were captured under ﬂuorescence using cell^P imaging software (Olympus, Japan). Magniﬁcation, 60. (A) Representative images.
Bar, 20 mm. (B) Data are shown as percentage area coverage and are mean  SD of n = 5 with separate blood donors. *P < 0.01 compared to collagen alone.
E. Liverani et al. / Biochemical Pharmacology 83 (2012) 1364–13731372secreted ADP. The inﬂuence of Pred on the complex relationship
between secreted ADP and TxA2 is an area that requires further
clariﬁcation.
Previously we have observed that cyclic nucleotide pathways,
particularly those activated through NO, also act through a similar
mechanism and adhesion is regulated through reduced TxA2
signaling and ADP bioavailability [14]. However, while Pred and
NO seemed to act in a similar manner, Pred did not exert its effects
through these pathways as evidenced by both its inability to
increase cAMP/cGMP concentrations and by the fact that
inhibitory actions were maintained under experimental condi-
tions where cyclic nucleotide signaling was blocked. In addition,
we measured NO species in the plasma of whole blood incubated
with Pred and aggregants, and found no modulation (data not
shown).
The adhesion and spreading of platelets on collagen are a
prerequisite for subsequent thrombus formation, which is also
known to require secondary signaling through ADP [13]. We
reasoned that since Pred was such an effective inhibitor of
spreading, it may also modulate thrombus formation. Our data
show – for the ﬁrst time – that Pred can exert dramatic effects
on accumulation of platelets under ﬂow. Indeed the effects of
Pred were arguably more potent under ﬂow than static
conditions. This may reﬂect the transient nature of the
interactions between platelets and collagen under ﬂow, wheresignaling events take place in ‘‘spikes’’ rather than the sustained
signaling, which takes places under static conditions. Thus, the
inhibitory actions of Pred, may not be potent when competing
with sustained activatory signaling, but under ﬂow its inhibitory
actions are magniﬁed as it is only competing with transient
signaling, enabling Pred to have a profound effect on thrombus
formation.
In conclusion, Pred can inhibit platelet adhesion, spreading,
aggregation, thrombus formation, and their interaction with
monocytes, through a novel mechanism that targets secondary
signaling. Initial evidence seems to point to the P2Y12 providing
guidance for our follow up studies. In any case, our current
observations are highly relevant to cardiovascular and inﬂam-
matory clinical settings and set the basis for further investiga-
tion aiming to detail Pred mechanism of action. The last point
could be particularly true in view of the fact that Pred is the
most widely used GC in the clinical environment.
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